Menu

卡博替尼多少钱一盒

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

How much does a box of Bangladesh Beacon Edition cost? Cabozantinib (XL184, Cabozantinib) in Bangladesh is priced at about $6,450 for 20mg*90 capsules, and about $7,400 for 80mg*30 capsules. Since the exchange rate is floating and the price is not fixed, if patients want to know the specific price information of the drug, they can consult the medical companion travel service.

At present, cabozantinib (XL184, Cabozantinib) has proven good therapeutic effects in a variety of solid tumors such as kidney cancer, thyroid cancer, liver cancer, soft tissue sarcoma, non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, intestinal cancer, and is particularly effective in controlling bone metastasis. Cabozantinib (XL184, Cabozantinib) is known as the "Taiwan Balm" among targeted drugs because of its broad effectiveness against a variety of cancers.

Approved Indications for Cabozantinib: The U.S. FDA approved Cabozantinib (XL184, Cabozantinib) capsules (140 mg/day) in 2012 for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC), and in 2016, the US FDA approved Cabozantinib (XL184, Cabozantinib) ) tablets (60 mg/day) for the treatment of patients with advanced renal cell carcinoma (RCC) who have received anti-angiogenic therapy. Cabozantinib (XL184, Cabozantinib) tablets (60 mg/day) were approved in 2018 for the treatment of patients with advanced hepatocellular carcinoma (RCC) who have progressed after receiving sorafenib or other standard systemic therapies.

Treatment of bone metastasis: Cabozantinib (XL184, Cabozantinib) acts on many molecular targets, some of which are involved in the formation of bone metastasis. It has a good ability to control bone metastasis of solid tumors and has been widely used in the treatment of renal cell carcinoma bone metastasis and prostate cancer bone metastasis.

(XL184, Cabozantinib) has remarkable therapeutic effects, and the successful development of this drug is good news for many patients. However, patients cannot blindly take this drug for treatment.

Recommended related hot articles: /newsDetail/81379.html

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。